Novartis files patent suit against Biocon over diabetes drug
Apr 03 2014 , Zurich
The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.
In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.
Galvus is one of Novartis' best-selling medicines, achieving $1.2 billion of sales last year.